Understanding Parkinson’s disease and its silent progression Parkinson’s disease is a neurodegenerative condition that mainly ...
TUCSON, Ariz., March 10, 2026– Critical Path Institute® (C-Path) applauds the publication of a new study in the Journal of Neurology that offers critical longitudinal insights into how symptoms and ...
A diabetes drug called lixisenatide has produced the first strong clinical evidence that a small molecule can slow the actual progression of Parkinson’s disease, not simply mask its symptoms. In a ...
Dr. Jamie Adams, MD, Study Senior Author, Critical Path Institute Longitudinal tracking of participants was grounded in the use of wearable devices to assess real-world experiences of people with ...
Scientists have identified a protective brain pathway that may help slow the progression of Parkinson's disease by strengthening the brain's own dopamine‑producing neurons, but the positive effect was ...
Can targeting α-synuclein slow the course of Parkinson’s disease? Despite years of trying, success has eluded scientists thus far. At the AD/PD conference, held March 17-21 in Copenhagen, Denmark, ...
This symposium reviewed the evolving understanding of the molecular pathophysiology and disease heterogeneity across Alzheimer's disease (AD) and Parkinson's disease (PD). Explored current and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results